Malignant Pleural Mesothelioma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Malignant Pleural Mesothelioma Overview
Malignant pleura Mesothelioma (MPM) is an aggressive cancer arising from the mesothelial cells of the pleura. The pleura is thin cellular lining than envelops both the lung (termed the “visceral” pleura) and chest wall (the “parietal” pleura), as well as the diaphragm, and the heart and major blood vessels in the central portion of the chest.
“Malignant Pleural Mesothelioma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.
The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years. Malignant Pleural Mesothelioma Key players such as – Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment
- Malignant Pleural Mesothelioma Emerging therapies such as – INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.
- In March 2021, Merck & Co initiated a Pembrolizumab plus Lenvatinib in second line and third line Malignant Pleural mesothelioma patients (PEMMELA). Currently the trial is active, not recruitingHowever the primary completion date was August 2022 with 38 participants.
Route of Administration
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment
- Malignant Pleural Mesothelioma Assessment by Product Type
- Malignant Pleural Mesothelioma By Stage and Product Type
- Malignant Pleural Mesothelioma Assessment by Route of Administration
- Malignant Pleural Mesothelioma By Stage and Route of Administration
- Malignant Pleural Mesothelioma Assessment by Molecule Type
- Malignant Pleural Mesothelioma by Stage and Molecule Type
DelveInsight’s Malignant Pleural Mesothelioma Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:
Key companies developing therapies for the Malignant Pleural Mesothelioma treatment are – Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis, MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others
Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:
- INBRX-109: Inhibrx
- NX-1607: Nurix Therapeutics
- ATA2271: Atara Biotherapeutics
- TC-510: TCR2 Therapeutics
- RSO-021: RS Oncology
- SAR-444245: Sanofi
- MTG201: MomotaroGene
- Durvalumab: AstraZeneca
- Pembrolizumab: Merck & Co
Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight
Malignant Pleural Mesothelioma Pipeline Analysis:
The Malignant Pleural Mesothelioma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
- Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies
Malignant Pleural Mesothelioma Pipeline Market Drivers
- Increased adoption of combination therapies
Malignant Pleural Mesothelioma Pipeline Market Barriers
- Treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem
- High Cost of Treatment
Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight
- Coverage: Global
- Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, and others
- Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, and others
- Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
- Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials
Table of Contents
1 |
Malignant Pleural Mesothelioma Report Introduction |
2 |
Malignant Pleural Mesothelioma Executive Summary |
3 |
Malignant Pleural Mesothelioma Overview |
4 |
Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment |
5 |
Malignant Pleural Mesothelioma Pipeline Therapeutics |
6 |
Malignant Pleural Mesothelioma Late Stage Products (Phase II/III) |
7 |
Malignant Pleural Mesothelioma Mid Stage Products (Phase II) |
8 |
Malignant Pleural Mesothelioma Early Stage Products (Phase I) |
9 |
Malignant Pleural Mesothelioma Preclinical Stage Products |
10 |
Malignant Pleural Mesothelioma Therapeutics Assessment |
11 |
Malignant Pleural Mesothelioma Inactive Products |
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
13 |
Malignant Pleural Mesothelioma Key Companies |
14 |
Malignant Pleural Mesothelioma Key Products |
15 |
Malignant Pleural Mesothelioma Unmet Needs |
16 |
Malignant Pleural Mesothelioma Market Drivers and Barriers |
17 |
Malignant Pleural Mesothelioma Future Perspectives and Conclusion |
18 |
Malignant Pleural Mesothelioma Analyst Views |
19 |
Appendix |
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services